Delfi Diagnostics has raised $225 million in a series B round to develop its liquid biopsy test. The Baltimore, MD-based company has now raised a little more than $325 million for its early cancer ...
IRVINE, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as well as its liquid biopsy profiles for ...
Predicine has launched its CE-marked PredicineCARE for genomic profiling in blood and urine in Europe. The cell free DNA (cfDNA) assay is a targeted next-generation sequencing (NGS) assay for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback